Latest Conference Articles

At DCAT With Piramal Pharma Solutions

May 13th 2024

Peter DeYoung, CEO, Piramal Pharma Solutions, talks about recent company achievements and key offerings, as well as current industry trends.

Research Shows that HIC Can Effectively Separate Deaminated Capsids from Non-Deaminated Capsids (ASGCT 2024)

May 11th 2024

The separation of deamidated capsids from non-deamidated capsids can be achieved using HIC, according to studies done by a team at Oxford Biomedica.

Using Receptor Architecture to Improve CAR-T Cell Sensitivity in Oncology (ASGCT 2024)

May 11th 2024

Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.

The Role of Bispecific Antibodies in Redirecting AAV Vectors (ASGCT 2024)

May 11th 2024

Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.

Embedding Sustainability in Drug Delivery through Industry Consensus at CPHI NA

May 10th 2024

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

CPHI North America: Industry Trends, Agenda Additions, and What to Expect at CPHI Milan

May 9th 2024

Tara Dougal, content director, Pharma, Informa Markets, discusses successes and insights from this year’s CPHI North America and the agenda for the upcoming CPHI Milan.

Interpreting Regulations and Meeting FDA Requirements at CPHI North America

May 9th 2024

Purna Thakker, founder and CEO of ADPT Solution, discusses common issues that companies face with FDA regulations at CPHI North America.

Regeneron Presents Update on Gene Therapy for Genetic Deafness at ASGCT

May 9th 2024

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

ASGCT 2024: Additives Play a Role in Removal of Empty and Partial AAV Capsids

May 8th 2024

Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production.

Data for First-in-Class IV-Administered Gene Therapy to Treat Epilepsy Presented at ASGCT 2024

May 8th 2024

The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.